Choline C-11: Pulling back the curtain on prostate cancer May 22, 2014 Overview إظهار النسخة النصية Overview About 90,000 men annually seek treatment for recurrent prostate cancer, according to the Surveillance, Epidemiology, and End Results Program. Recurrent prostate cancer is defined as cancer that has recurred following initial therapy, which could include surgery, radiation therapy, hormone therapy or chemotherapy. Choline C 11 Injection has a short shelf life and must be made in a specialized facility and given to patients within minutes after production. Mayo Clinic has the integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to patients. VID-20439984 المتخصصون في المجالات الطبية Choline C-11: Pulling Back the Curtain on Prostate Cancer